Sector: HealthcareIndustry: Drug Manufacturers - GeneralCIK:0000875045
Market Cap28.23 Bn
P/E20.51
P/S2.84
Div. Yield0.00
ROIC (Qtr)0.00
Revenue Growth (1y) (Qtr)1.93
Add ratio to table...
About
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. The company has a broad portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, co-developed treatments to address a defining pathology of Alzheimer's disease and launched the first approved treatment to target a genetic cause of amyotrophic lateral sclerosis. Biogen markets the first and only drug approved in the...
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. The company has a broad portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, co-developed treatments to address a defining pathology of Alzheimer's disease and launched the first approved treatment to target a genetic cause of amyotrophic lateral sclerosis. Biogen markets the first and only drug approved in the U. S., the E. U. and certain international markets for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. The company is focused on advancing its pipeline in neurology, specialized immunology and rare diseases.
Biogen generates revenue through the sale of its marketed products, including VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; SKYCLARYS for the treatment of Friedreich's ataxia; and QALSODY for the treatment of amyotrophic lateral sclerosis. The company also earns revenue from collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and with Supernus on the commercialization of ZURZUVAE for the treatment of postpartum depression. Biogen has certain business and financial rights with respect to RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS and LUNSUMIO for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The company commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE.
Biogen operates through the following segments: Multiple Sclerosis, Alzheimer's Disease, Neuropsychiatry, Rare Disease, Biosimilars and Anti-CD20 Therapeutic Programs.
• The Multiple Sclerosis segment includes products designed to treat patients with MS such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY and TYSABRI targeting relapsing remitting MS in the U. S. and major European markets including France, Germany, Italy, Spain, Switzerland and the U. K.
• The Alzheimer's Disease segment includes LEQEMBI for the treatment of early Alzheimer's disease developed and commercialized in collaboration with Eisai with major markets in the U. S., China, Japan and South Korea.
• The Neuropsychiatry segment includes ZURZUVAE for the treatment of postpartum depression in adults developed in collaboration with Supernus with major markets in the U. S.
• The Rare Disease segment includes SPINRAZA for spinal muscular atrophy, QALSODY for amyotrophic lateral sclerosis with SOD1 mutations and SKYCLARYS for Friedreich's ataxia with major markets in the U. S., Brazil, France, Germany, Italy, Poland, Greece and Turkey for SMA; U. S., France, Germany, Greece, Italy and Turkey for FA; and U. S., China, Germany, Japan and Spain for ALS.
• The Biosimilars segment includes BENEPALI, IMRALDI and FLIXABI commercialized pursuant to an agreement with Samsung Bioepis targeting rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and pediatric indications in France, Germany, Italy, Spain, Sweden and the U. K.
• The Anti-CD20 Therapeutic Programs segment includes RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO and COLUMVI for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic lymphoma and other conditions with major markets in the U. S.
Biogen holds a strong position within the biopharmaceutical industry due to its pioneering therapies in neurology and rare diseases. The company faces intense competition from other biotechnology and pharmaceutical companies developing products for similar indications. Competitors include Eli Lilly and Company with KISUNLA for Alzheimer's disease, and companies offering oral and gene therapy alternatives such as EVRYSDI and ZOLGENSMA for spinal muscular atrophy. Biogen's competitive advantages stem from its scientific innovation, established patent positions and ability to manufacture and market complex biologics effectively.
Biogen serves patients, healthcare providers, hospitals and specialty clinics globally. The company distributes its products in the U. S. principally through wholesale and specialty distributors of pharmaceutical products and specialty pharmacies. In international markets, distribution varies by country and includes wholesale distributors and third-party partners. Biogen's product sales to two wholesale distributors each accounted for more than 10.0% of its total revenue in recent years.
Biogen’s recent 19% growth product revenue rise demonstrates that the company’s “bridge to growth” strategy is already bearing fruit, especially with the launch of LECANEMAB, SKYCLARIS, ZERZUVE, and CALSADI contributing more than $1 billion in sales. The company’s disciplined expense management, reflected in flat core operating expenses for 2026, suggests that margin expansion will follow as revenue scales, allowing the firm to invest further in high‑conviction late‑stage assets while also returning capital to shareholders. This is reinforced by the $4.2 billion cash balance and $2 billion net debt, giving Biogen the flexibility to pursue share buybacks or strategic acquisitions of $5–$6 billion assets that could accelerate the pipeline and expand its therapeutic footprint.
The subcutaneous “iClick” PDUFA date in May 2026 positions LECANEMAB for a broader, more convenient delivery platform that could substantially increase patient uptake once full Part D reimbursement is granted in 2027. Early uptake of the subcutaneous maintenance formulation already shows a 70% persistence rate, indicating strong patient adherence that is likely to translate into steady revenue growth. The potential for an induction formulation, pending approval, would create a single‑injection therapy that could dominate the anti‑amyloid market and capture patients who currently avoid intravenous infusion centers, further boosting sales.
SPINRAZA high‑dose approval in the United States and the swift uptake in Japan provide a valuable “high‑dose” launch experience that could be replicated in other rare disease markets. The early signs of switch‑back from intrathecal to oral therapy in Japan indicate that physicians and payers are willing to shift to the more convenient oral route, signaling an opportunity for similar adoption in the U.S. market. With the PDUFA for high‑dose in the U.S. set for April 2026, Biogen stands to capture early revenue in a high‑margin niche, further reducing dependence on legacy MS drugs.
The company’s immunology expansion through acquisitions such as Alcion Therapeutics and partnerships with Vanqua and Dara Therapeutics diversifies its product pipeline beyond neurology, targeting unmet needs in lupus, kidney transplant rejection, and rare immune disorders. These collaborations bring early‑commercialization‑ready assets that can quickly translate into revenue streams, particularly as the U.S. launch of lupus and nephrology products approaches in 2026–27. The pipeline’s high‑conviction assets, such as LADAfilumab (SLE) and LAMRF (AMR), have already shown promising data, positioning Biogen to launch novel treatments that could generate high margin revenue and create a new growth engine.
Biogen’s commitment to early-stage innovation, evidenced by the launch of BTK degrader and other phase‑I programs, establishes a long‑term value creation pathway that may pay dividends beyond the next few years. By focusing on high‑risk, high‑reward assets and maintaining a robust R&D pipeline, Biogen protects itself against the erosion of legacy products and prepares to capture future therapeutic breakthroughs in ALS, Alzheimer’s, and other neurodegenerative diseases. The company’s strategy to shift resources from legacy MS to growth products aligns with the industry’s broader shift towards precision and patient‑centric therapies, ensuring that Biogen remains competitive in a rapidly evolving therapeutic landscape.
Biogen’s recent 19% growth product revenue rise demonstrates that the company’s “bridge to growth” strategy is already bearing fruit, especially with the launch of LECANEMAB, SKYCLARIS, ZERZUVE, and CALSADI contributing more than $1 billion in sales. The company’s disciplined expense management, reflected in flat core operating expenses for 2026, suggests that margin expansion will follow as revenue scales, allowing the firm to invest further in high‑conviction late‑stage assets while also returning capital to shareholders. This is reinforced by the $4.2 billion cash balance and $2 billion net debt, giving Biogen the flexibility to pursue share buybacks or strategic acquisitions of $5–$6 billion assets that could accelerate the pipeline and expand its therapeutic footprint.
The subcutaneous “iClick” PDUFA date in May 2026 positions LECANEMAB for a broader, more convenient delivery platform that could substantially increase patient uptake once full Part D reimbursement is granted in 2027. Early uptake of the subcutaneous maintenance formulation already shows a 70% persistence rate, indicating strong patient adherence that is likely to translate into steady revenue growth. The potential for an induction formulation, pending approval, would create a single‑injection therapy that could dominate the anti‑amyloid market and capture patients who currently avoid intravenous infusion centers, further boosting sales.
SPINRAZA high‑dose approval in the United States and the swift uptake in Japan provide a valuable “high‑dose” launch experience that could be replicated in other rare disease markets. The early signs of switch‑back from intrathecal to oral therapy in Japan indicate that physicians and payers are willing to shift to the more convenient oral route, signaling an opportunity for similar adoption in the U.S. market. With the PDUFA for high‑dose in the U.S. set for April 2026, Biogen stands to capture early revenue in a high‑margin niche, further reducing dependence on legacy MS drugs.
The company’s immunology expansion through acquisitions such as Alcion Therapeutics and partnerships with Vanqua and Dara Therapeutics diversifies its product pipeline beyond neurology, targeting unmet needs in lupus, kidney transplant rejection, and rare immune disorders. These collaborations bring early‑commercialization‑ready assets that can quickly translate into revenue streams, particularly as the U.S. launch of lupus and nephrology products approaches in 2026–27. The pipeline’s high‑conviction assets, such as LADAfilumab (SLE) and LAMRF (AMR), have already shown promising data, positioning Biogen to launch novel treatments that could generate high margin revenue and create a new growth engine.
Biogen’s commitment to early-stage innovation, evidenced by the launch of BTK degrader and other phase‑I programs, establishes a long‑term value creation pathway that may pay dividends beyond the next few years. By focusing on high‑risk, high‑reward assets and maintaining a robust R&D pipeline, Biogen protects itself against the erosion of legacy products and prepares to capture future therapeutic breakthroughs in ALS, Alzheimer’s, and other neurodegenerative diseases. The company’s strategy to shift resources from legacy MS to growth products aligns with the industry’s broader shift towards precision and patient‑centric therapies, ensuring that Biogen remains competitive in a rapidly evolving therapeutic landscape.
Biogen’s revenue outlook for 2026 signals a mid‑single‑digit decline, driven by ongoing generic erosion of its flagship multiple sclerosis portfolio and biosimilar competition for Tysabri. This downward trajectory highlights the fragility of Biogen’s core revenue base, suggesting that growth from newer products may not offset the erosion of legacy sales, especially if patient switching to generics accelerates. The company’s guidance reflects an explicit acknowledgment of these pressures, which could undermine investor confidence if legacy erosion outpaces new product uptake.
The company’s heavy reliance on subcutaneous LECANEMAB rollout is contingent on full Part D reimbursement, which is not expected until 2027. Until that point, payer uncertainty and formulary restrictions could limit market penetration, creating a revenue lag for a product that is central to Biogen’s growth strategy. The Q&A revealed a lack of concrete data on uptake rates post‑reimbursement, exposing a significant unspoken risk that could delay or dampen the expected sales boost.
Biogen’s late‑stage pipeline, while high‑conviction, remains heavily dependent on uncertain regulatory approvals and clinical outcomes. Several key assets—such as LADAfilumab for SLE, LAMRF for AMR, and BIB 80 for Alzheimer’s—lack robust, phase‑III data and may face challenges in demonstrating clinical benefit or safety. The company's acknowledgment that "data are still pending" underscores a high failure risk, potentially leading to missed launch opportunities and wasted capital.
The company has incurred significant one‑time charges, including $180 million in litigation and $222 million in IPR&D charges, which eroded earnings and demonstrate a pattern of unpredictable, non‑recurring expenses. These costs highlight management’s potential exposure to legal and regulatory liabilities that could materially impact future profitability. Moreover, the reliance on one‑time charges to offset earnings suggests that the company may face similar charges in the future, undermining earnings consistency.
Biogen’s global manufacturing and distribution strategy faces potential supply chain risks, especially as it expands into new indications. The company has noted shipment timing issues and pricing adjustments for SPINRAZA and SKYCLARIS, which may become more pronounced as it attempts to scale production and secure international market access. Any disruptions in supply could hurt sales, erode margins, and damage the brand's reputation, particularly in markets with tight reimbursement environments.
Biogen’s revenue outlook for 2026 signals a mid‑single‑digit decline, driven by ongoing generic erosion of its flagship multiple sclerosis portfolio and biosimilar competition for Tysabri. This downward trajectory highlights the fragility of Biogen’s core revenue base, suggesting that growth from newer products may not offset the erosion of legacy sales, especially if patient switching to generics accelerates. The company’s guidance reflects an explicit acknowledgment of these pressures, which could undermine investor confidence if legacy erosion outpaces new product uptake.
The company’s heavy reliance on subcutaneous LECANEMAB rollout is contingent on full Part D reimbursement, which is not expected until 2027. Until that point, payer uncertainty and formulary restrictions could limit market penetration, creating a revenue lag for a product that is central to Biogen’s growth strategy. The Q&A revealed a lack of concrete data on uptake rates post‑reimbursement, exposing a significant unspoken risk that could delay or dampen the expected sales boost.
Biogen’s late‑stage pipeline, while high‑conviction, remains heavily dependent on uncertain regulatory approvals and clinical outcomes. Several key assets—such as LADAfilumab for SLE, LAMRF for AMR, and BIB 80 for Alzheimer’s—lack robust, phase‑III data and may face challenges in demonstrating clinical benefit or safety. The company's acknowledgment that "data are still pending" underscores a high failure risk, potentially leading to missed launch opportunities and wasted capital.
The company has incurred significant one‑time charges, including $180 million in litigation and $222 million in IPR&D charges, which eroded earnings and demonstrate a pattern of unpredictable, non‑recurring expenses. These costs highlight management’s potential exposure to legal and regulatory liabilities that could materially impact future profitability. Moreover, the reliance on one‑time charges to offset earnings suggests that the company may face similar charges in the future, undermining earnings consistency.
Biogen’s global manufacturing and distribution strategy faces potential supply chain risks, especially as it expands into new indications. The company has noted shipment timing issues and pricing adjustments for SPINRAZA and SKYCLARIS, which may become more pronounced as it attempts to scale production and secure international market access. Any disruptions in supply could hurt sales, erode margins, and damage the brand's reputation, particularly in markets with tight reimbursement environments.